Supernus Pharmaceuticals, Inc.
SUPN
Κατάταξη σε μετοχές
#5895
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Τιμή μετοχής
$37.86
Τελευταίος συγχρονισμός: 2026-10-16
Κεφαλαιοποίηση
$2.20B
Αλλαγή (1 ημέρα)
-4.32%
Αλλαγή (1 έτος)
-23.08%
Χώρα
US
Εμπόριο Supernus Pharmaceuticals, Inc. (SUPN)
Κατηγορία
Healthcare
Κεφαλαιοποίηση αγοράς του Supernus Pharmaceuticals, Inc.(SUPN)
Κεφαλαιοποίηση: $2.20B
Μέχρι το October 2026, η Supernus Pharmaceuticals, Inc. έχει χρηματιστηριακή αξία $2.20B. Αυτό καθιστά τη Supernus Pharmaceuticals, Inc. την 5895th πιο πολύτιμη εταιρεία στον κόσμο βάσει της κεφαλαιοποίησης σύμφωνα με τα δεδομένα μας. Η χρηματιστηριακή κεφαλαιοποίηση είναι η συνολική αγοραία αξία των μετοχών μιας εισηγμένης εταιρείας και χρησιμοποιείται συνήθως για να προσδιοριστεί η αξία μιας εταιρείας.
Ιστορικό κεφαλαιοποίησης αγοράς της Supernus Pharmaceuticals, Inc. από 2018 έως 2026
SUPN σε σύγκριση με τα 5 πιο δημοφιλή stocks
| Η τιμή για SUPN | Το περιουσιακό στοιχείο B | Η κεφαλαιοποίηση αγοράς του B | Αποτελέσματα | |
|---|---|---|---|---|
$88,744.01
$2.24B
|
$5.167T | +230,104.96% | ||
|
$86,128.93
$2.24B
|
$5.015T | +223,321.34% | ||
|
$70,561.89
$2.24B
|
$4.108T | +182,939.91% | ||
|
$67,015.27
$2.24B
|
$3.902T | +173,739.88% | ||
|
$46,191.46
$2.24B
|
$2.689T | +119,722.20% |
